Traduction de «médicament favorisant la diurèse » (Français → Anglais) :

(Return tabled) Question No. 530 Ms. Anne Minh-Thu Quach: With regard to Health Canada and the drug shortage: (a) what are the various plans that have been brought forward since 1990 to address drug shortages; (b) based on which studies is the Minister promoting a voluntary reporting mechanism for the industry to address drug shortages; (c) what are Health Canada’s budgets for inspecting drug manufacturing plants; (d) does Health Canada have a budget for identifying new emergency suppliers in case of a shortage; (e) what are Health Canada’s preferred contingency plans in the event of a sudden production shutdown, such as a bankruptcy ...[+++] or a plant fire; (f) since a few producers are the only ones to produce a given drug, what recourse does Health Canada have if a sudden production shutdown affects a sole producer of a drug; (g) what are the fast-track mechanisms for identifying alternatives for drugs in short supply; (h) in the event of a shortage, how does Health Canada prioritize its shipments of stockpiled products; (i) if there is no surplus inventory and if there is no alternate manufacturer, how does Health Canada determine who has the greatest need for the drugs; (j) what solutions based on what is done in other countries around the world have been considered by Health Canada; and (k) has Health Canada considered a solution based on the Swedish model, where a state-owned corporation produces about 2 percent of the country’s demand for drugs?

- shall encourage the rational use of the medicinal product, by presenting it objectively and without exaggerating its properties,

In addition to registering drugs and giving public information, the drugs directorate through its bureau of drug surveillance promotes and supports the safe and rational use of drugs after they enter the market and are in the public domain.

On 22nd July, the Council reached a political agreement, with a view to achieving a common position, on the content of four proposals designed to promote a more rational use of medicines in the Community, namely: - labelling and information on medicines; - legal status of medicines (prescription or non-prescription); - wholesale distribution of medicines; - advertising of medicines for human use.

The Commission has taken the initiative, within the context of its policy on the rational use of medicines, of proposing Community legislation to improve the information available to consumers on medicines and to facilitate the free intra Community trade of medicines, as part of the achievement of a single market.

The Committee therefore commends a series of strategies in favour of a support policy for the sector to the Commission and the European Medicines Evaluation Agency. They may be summarized as follows: - general policy: . reflecting the objectives and priorities of medical treatment; . strengthening the Commission's work to provide guidance on decisions to be made by national bodies, encouraging a process of convergence; - social policy: . a future guarantee of equal availability of medicines to all European citizens; . social protection arrangements adapted to the need for a high level of health protection; - industrial policy: . cond ...[+++]itions enabling the pharmaceutical industry to become highly competitive with its US and Japanese counterparts; . encouraging expanding employment within the sector.